Curetis to Present at Key Investor and Scientific Conferences in the First Quarter 2017
(Thomson Reuters ONE) -
Curetis /
Curetis to Present at Key Investor and Scientific Conferences in the First
Quarter 2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Curetis to Present at Key Investor and Scientific Conferences in the First
Quarter 2017
Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 4, 2017 --
Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a
developer of next-level molecular diagnostic solutions, today announced its
participation in several industry conferences in the first quarter of 2017. The
respective presentations will be made available on the company's website.
January:
J.P. Morgan 35th Annual Healthcare Conference 2017, January 9-13, 2017 - San
Francisco, CA, USA: one-on-one meetings.
Society of Critical Care Medicine's (SCCM) 46th Critical Care Congress, January
21-25, 2017 - Honolulu, Hawaii, USA: exhibition booth: 924.
Invest Securities BioMed Event, January 26, 2017 - Paris, France: company
presentation and one-on-one meetings.
DeGroof Petercam Life Sciences Investor Day, January 31, 2017 - Brussels,
Belgium: one-on-one meetings.
February:
3rd Annual Medtech & Money Healthcare Conference, February 7-8, 2017 - London,
United Kingdom: company presentation and one-on-one meetings.
BIO CEO & Investor Conference, February 13-14, 2017 - New York, NY, USA: company
presentation and one-on-one meetings.
RBC Healthcare Conference 2017, February 22-23, 2017 - New York, NY, USA:
company presentation and one-on-one meetings.
March:
Microbiology and Infection 2017; 5th Joint Conference of the DGHM & VAAM
VAAM Annual Meeting 2017; 69th Annual Meeting of the DGHM, March 5-8, 2017 -
Wuerzburg, Germany.
Sachs 10th European Life Science CEO Forum & Exhibition, March 6-7, 2017 -
Basel, Switzerland: company presentation and one-on-one meetings.
BioCapital Europe 2017, March 15, 2017 - Amsterdam, The Netherlands: company
presentation and one-on-one meetings.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million.
Furthermore, Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis has signed collaboration agreements with Heraeus Medical and
Cempra Inc. as well as several international distribution agreements covering
many countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Curetis_Logo:
http://hugin.info/171382/R/2068757/776958.jpg
20170104_Curetis_PR_EN_02:
http://hugin.info/171382/R/2068757/776954.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 04.01.2017 - 07:56 Uhr
Sprache: Deutsch
News-ID 515696
Anzahl Zeichen: 6363
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 165 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis to Present at Key Investor and Scientific Conferences in the First Quarter 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
